FDA approves Ionis’ RNA-targeting therapy to treat rare disease that causes swelling attacksnews2025-08-21T16:58:21+00:00August 21st, 2025|Endpoints News|
HHS staffers blame RFK Jr. for ‘deliberate destruction’ of trustnews2025-08-20T19:14:24+00:00August 20th, 2025|Endpoints News|
FDA lifts hold on Rocket’s pivotal study for its gene therapy, which is now a lower dosenews2025-08-20T14:59:39+00:00August 20th, 2025|Endpoints News|
Researchers cited by HHS on mRNA cuts say their work is misappliednews2025-08-19T17:17:01+00:00August 19th, 2025|Endpoints News|
FDA rejects PTC’s Friedreich’s ataxia drugnews2025-08-19T13:45:51+00:00August 19th, 2025|Endpoints News|
FDA delays decision on Regenxbio’s Hunter syndrome gene therapy by three monthsnews2025-08-18T21:00:56+00:00August 18th, 2025|Endpoints News|
How the draft MAHA Commission recommendations may impact pharmanews2025-08-18T19:17:21+00:00August 18th, 2025|Endpoints News|
Conflicts among US vaccine advisors declined through 2024, new research showsnews2025-08-18T15:00:37+00:00August 18th, 2025|Endpoints News|
Novo Nordisk’s Wegovy is the second drug approved in MASHnews2025-08-18T10:50:09+00:00August 18th, 2025|Endpoints News|
Precigen’s rare disease therapy gets full approval from the FDAnews2025-08-15T15:31:43+00:00August 15th, 2025|Endpoints News|
